1 |
WALSH D R, NOLIN T D, FRIEDMAN P A. Drug transporters and Na+/H+ exchange regulatory factor PSD-95/drosophila discs large/ZO-1 proteins[J]. Pharmacol Rev, 2015, 67(3):656-680.
|
2 |
AVRAM S, HALIP L, CURPAN R, et al. Novel drug targets in 2019[J].Nat Rev Drug Discov,2020,19(5):300.
|
3 |
张 帅,刘晓亮,房舒舒,等.SGLT2抑制剂坎格列净的临床应用研究进展[J].中国医院药学杂志,2016,36(5):412-417.
|
4 |
朱思梅,杨汉跃,王建涛.SGLT1/SGLT2双重抑制剂索格列净用于1型糖尿病的研究进展[J].中国新药与临床杂志,2018,37(10):537-540.
|
5 |
NIGAM S K. What do drug transporters really do? [J]. Nat Rev Drug Discov, 2015, 14(1): 29-44.
|
6 |
INTERNATIONAL TRANSPORTER CONSORTIUM, GIACOMINI K M, HUANG S M, et al. Membrane transporters in drug development[J]. Nat Rev Drug Discov, 2010, 9(3): 215-236.
|
7 |
李 聃,盛 莉,李 燕.药物转运体的研究方法[J].药学学报,2014,49(7):963-970.
|
8 |
DING Y, WANG R, ZHANG J, et al. Potential regulation mechanisms of P-gp in the blood-brain barrier in hypoxia[J]. Curr Pharm Des, 2019,25(10):1041-1051.
|
9 |
伊秀林,司端运,刘昌孝. 应用药物转运体的药代动力学评价[J]. 药物评价研究,2010,33(5):341-346.
|
10 |
董月柳, 刘 洋, 尹秀文, 等. 基于P-糖蛋白的肠吸收在体单向肠灌流模型验证[J].中国中药杂志,2017,42(8):1539-1544.
|
11 |
BAUMAN J L, DIDOMENICO R J, GALANTER W L.Mechanisms, manifestations, and management of digoxin toxicity in the modern era[J]. Am J Cardiovasc Drugs, 2006, 6(2):77-86.
|
12 |
DRESCHER S, GLAESER H, HITZL M, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans[J]. Clin Pharmacol Ther, 2003,73(3):223-231.
|
13 |
张 健,刘克辛.药物转运体介导的小肠吸收、肾脏排泄与药物相互作用的关系[J].药学学报,2010,45(9):1089-1094.
|
14 |
HU Y, SMITH D E, MA K, et al. Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine[J]. Mol Pharm, 2008, 5(6): 1122-1130.
|
15 |
HU M, AMIDON G L. Passive and carrier-mediated intestinal absorption components of captopril[J].J Pharm Sci, 1988, 77(12): 1007-1011.
|
16 |
LIU H, XU X, YANG Z, et al. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats[J]. Brain Res, 2006, 1123(1):245-252.
|
17 |
CHANDRA P, BROUWER K L. The complexities of hepatic drug transport: current knowledge and emerging concepts[J]. Pharm Res, 2004, 21(5):719-735.
|
18 |
NIEMI M, PASANEN M K, NEUVONEN P J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake[J].Pharmacol Rev,2011,63(1):157-181.
|
19 |
HUANG P, ZHANG L, GAO Y, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes[J]. Cell Stem Cell, 2014, 14(3):370-384.
|
20 |
SHITARA Y, MAEDA K, IKEJIRI K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption[J]. Biopharm Drug Dispos,2013,34(1):45-78.
|
21 |
NIEDERMEYER T H, DAILY A, SWIATECKA-HAGENBRUCH M, et al. Selectivity and potency of microcystin congeners against OATP1B1 and OATP1B3 expressing cancer cells[J]. PLoS One, 2014, 9(3): e91476.
|
22 |
MAEDA K, IKEDA Y, FUJITA T, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study[J]. Clin Pharmacol Ther, 2011, 90(4): 575-581.
|
23 |
CATAPANO A L. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin[J]. Curr Vasc Pharmacol,2012,10(2):257-267.
|
24 |
IVANYUK A, LIVIO F, BIOLLAZ J, et al. Renal drug transporters and drug interactions[J]. Clin Pharmacokinet,2017,56(8): 825-892.
|
25 |
FROMM M F, KIM R B, STEIN C M, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine[J]. Circulation,1999,99:552-557.
|
26 |
母义明,纪立农,宁 光,等.二甲双胍临床应用专家共识(2016年版)[J].中国糖尿病杂志,2016,24(10): 871-884.
|
27 |
ITO S, KUSUHARA H, YOKOCHI M, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney[J]. J Pharmacol Exp Ther, 2012, 340(2):393-403.
|
28 |
KUSUHARA H, ITO S, KUMAGAI Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects[J]. Clin Pharmacol Ther, 2011, 89(6): 837-844.
|
29 |
SONG I H, ZONG J, BORLAND J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects[J]. J Acquir Immune Defic Syndr, 2016, 72(4): 400-407.
|
30 |
SEVERIN M J, HAZELHOFF M H, BULACIO R P,et al. Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions[J]. Nephrol Carlton Vic, 2017, 22(8): 642-648.
|
31 |
KAWAGUCHI A, UGIMOTO K, OHMORI M,et al. Furosemide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology[J]. Clin Pharmacol Ther,2001,69(4):232-237.
|
32 |
RANIERI L, CONTERO C, PERAL M L, et al. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort[J]. Arthritis Res Ther, 2018, 20(1): 53.
|
33 |
LI M, ANDERSON G D, WANG J. Drug-drug interactions involving membrane transporters in the human kidney[J]. Expert Opin Drug Metab Toxicol, 2006, 2(4):505-532.
|
34 |
MORRISSEY K M, STOCKER S L, WITTWER M B,et al. Renal transporters in drug development[J]. Annu Rev Pharmacol Toxicol, 2013, 53: 503-529.
|
35 |
GO R S, ADJEI A A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin[J]. J Clin Oncol, 1999, 17(1):409-422.
|
36 |
MAKOVEC T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy[J]. Radiol Oncol,2019,53(2):148-158.
|
37 |
MANOHAR S, LEUNG N. Cisplatin nephrotoxicity: a review of the literature[J]. J Nephrol,2018,31(1):15-25.
|
38 |
YOKOO S, YONEZAWA A, MASUDA S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity[J].Biochem Pharmacol,2007,74(3):477-487.
|
39 |
CIARIMBOLI G, DEUSTER D, KNIEF A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions[J]. Am J Pathol,2010,176(3):1169-1180.
|
40 |
YIN J, WANG J. Renal drug transporters and their significance in drug-drug interactions[J]. Acta Pharm Sin B, 2016, 6(5): 363-373.
|
41 |
KIM A, CHUNG I, YOON S H, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics[J]. Drug Metab Dispos, 2014, 42(7):1174-1179.
|
42 |
HIRAMATSU S I, IKEMURA K, FUJISAWA Y,et al.Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats[J]. Biopharm Drug Dispos,2020,41(6): 239-247.
|
43 |
ZHANG L, HUANG S M, REYNOLDS K, et al. Transporters in drug development: scientific and regulatory considerations[J]. Clin Pharmacol Ther,2018,104(5):793-796.
|
44 |
YEE S W, BRACKMAN D J, ENNIS E A, et al. Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium[J]. Clin Pharmacol Ther, 2018, 104(5): 803-817.
|
45 |
NIEMI M, PASANEN M K, NEUVONEN P J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin[J]. Clin Pharmacol Ther,2006,80(4):356-366.
|
46 |
SHU Y, BROWN C, CASTRO R A, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics[J]. Clin Pharmacol Ther, 2008, 83(2):273-280.
|
47 |
张 师,王明霞,冯章英.酪氨酸激酶抑制剂药动学研究进展[J].中国新药杂志,2016,25(14):1600-1607.
|
48 |
HAMADA A, SASAKI J I, SAEKI S, et al. Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer[J]. Pharmacogenomics, 2012, 13(5): 615-624.
|
49 |
廖德华,符一岚,姚敦武,等.代谢酶及转运体基因多态性对厄洛替尼与吉非替尼治疗效果及毒副反应影响的研究进展[J].中南药学,2020,18(12):2027-2031.
|
50 |
GIACOMINI K M, GALETIN A, HUANG S M. The international transporter consortium: summarizing advances in the role of transporters in drug development[J]. Clin Pharmacol Ther, 2018, 104(5):766-771.
|
51 |
卢韵弘,陈莉明.SGLT2抑制剂与高尿酸血症[J]. 中国实用内科杂志,2020,40(8): 625-629.
|